Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5210285> ?p ?o }
Showing triples 1 to 27 of
27
with 100 triples per page.
- Q5210285 subject Q7403741.
- Q5210285 subject Q8253301.
- Q5210285 subject Q8852380.
- Q5210285 abstract "Dalcetrapib or JTT-705 is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012. The drug was aimed at raising the blood levels of "good cholesterol" (cholesterol carried in HDL particles, aka HDL-C). Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health.A 24-week clinical trial showed that dalcetrapib did increase HDL-C levels, supporting the agent's desired effect. Further, the dal-PLAQUE phase IIb trial found evidence of plaque reduction. Plaque reduction is an anticipated observation following an increase in HDL.As of 2010 five phase II trials had started and there was no evidence of the raised blood pressure seen with torcetrapib.dal-VESSEL phase IIb trial found no evidence of flow-mediated dilatation improvement. A 17% increase of Lp-PLA2 mass level was noted. Lp-PLA2 is associated with coronary heart disease and stroke.dal-OUTCOMES phase III trial passed its first interim review in July, 2011, however, development was halted on May 7, 2012 “due to a lack of clinically meaningful efficacy.”.The results of dal-OUTCOMES III were published in November, 2012.".
- Q5210285 iupacName "S-[2-({[1-(2-ethylbutyl)cyclohexyl]carbonyl}amino)phenyl] 2-methylpropanethioate".
- Q5210285 thumbnail JTT-705_structure.png?width=300.
- Q5210285 wikiPageWikiLink Q1058276.
- Q5210285 wikiPageWikiLink Q12202.
- Q5210285 wikiPageWikiLink Q18032676.
- Q5210285 wikiPageWikiLink Q212646.
- Q5210285 wikiPageWikiLink Q30612.
- Q5210285 wikiPageWikiLink Q410020.
- Q5210285 wikiPageWikiLink Q5010385.
- Q5210285 wikiPageWikiLink Q7403741.
- Q5210285 wikiPageWikiLink Q7825530.
- Q5210285 wikiPageWikiLink Q8253301.
- Q5210285 wikiPageWikiLink Q844935.
- Q5210285 wikiPageWikiLink Q8852380.
- Q5210285 iupacname "S-[2-phenyl] 2-methylpropanethioate".
- Q5210285 type ChemicalCompound.
- Q5210285 type ChemicalSubstance.
- Q5210285 type ChemicalObject.
- Q5210285 type Thing.
- Q5210285 type Q11173.
- Q5210285 comment "Dalcetrapib or JTT-705 is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012. The drug was aimed at raising the blood levels of "good cholesterol" (cholesterol carried in HDL particles, aka HDL-C).".
- Q5210285 label "Dalcetrapib".
- Q5210285 depiction JTT-705_structure.png.